This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

JDRF Through The Joint JDRF-Helmsley Charitable Trust Initiative Partners With Medtronic To Advance Continuous Glucose Monitoring Towards Artificial Pancreas Systems

Stocks in this article: MDT

-- Partnership Announced Between Leaders of Artificial Pancreas Research and Development to Develop Novel Redundant Sensor System to Help Improve Glucose Control for People with Diabetes --

NEW YORK, June 1, 2012 /PRNewswire-USNewswire/ -- JDRF in collaboration with the Helmsley Charitable Trust (HCT) announced today a partnership with Medtronic, Inc. (NYSE:MDT), a leader in artificial pancreas research and development. The JDRF-HCT Sensor Initiative aims to advance continuous glucose monitoring (CGM) accuracy and reliability towards the next generation artificial pancreas systems.

The goal of the partnership is to accelerate the development of Medtronic's novel redundant sensor system which combines two unique sensing technologies in one device. This major technological advance was awarded funding support from the JDRF-Helmsley Charitable Trust collaboration's Sensor Initiative. The JDRF-HCT Sensor Initiative was launched to accelerate the development and delivery of more accurate and reliable continuous glucose sensors. Continuous glucose sensors hold the potential to drive towards the development of future artificial pancreas systems for people with diabetes. Today's CGM devices have significantly helped improve glucose control in people with type 1 diabetes. Next generation sensors will provide improved accuracy and reliability, which will allow for more aggressive insulin management and support towards the development of automated artificial pancreas systems.

"Accurate and reliable sensor technology has long been identified as a necessity for the realization of an artificial pancreas. Medtronic's development of an orthogonally redundant sensor system will greatly accelerate this path," said Jeffrey Brewer, President and Chief Executive Officer of JDRF. "We are excited to bring our long-standing partnership with Medtronic to a new level through this Sensor Initiative, which could improve the outcomes of people with diabetes."

"The Helmsley Charitable Trust is committed to easing the burden and improving the quality of life of those living with type 1 diabetes; this collaboration provides the opportunity to accelerate the development of more accurate, effective tools to support day-to-day insulin management, which would accomplish both of our objectives," said David Panzirer, Trustee, Helmsley Charitable Trust. 

The orthogonally redundant sensor system will combine an electrochemical sensor – scientifically referred to as a glucose oxidase (GOX) sensor and the commonly used technology in CGM systems – with an optical sensor, to provide accurate, glucose values. By combining two distinctive measurement technologies, the two sensors function as a "check and balance" to enable true redundancy to ensure safe and reliable glucose measurements for an artificial pancreas system.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,677.90 +216.58 1.32%
S&P 500 1,950.82 +23.71 1.23%
NASDAQ 4,452.7920 +69.9450 1.60%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs